190 related articles for article (PubMed ID: 35426773)
1. COVID-19 immunization in people with cancer-Is it safe and efficient? What do we know?
Lazăr DE; Munteanu A
Tumori; 2022 Oct; 108(5):420-430. PubMed ID: 35426773
[TBL] [Abstract][Full Text] [Related]
2. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.
Hwang JK; Zhang T; Wang AZ; Li Z
J Hematol Oncol; 2021 Feb; 14(1):38. PubMed ID: 33640005
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 Vaccination in Children: An Open Question.
Campagnani G; Bardanzellu F; Pintus MC; Fanos V; Marcialis MA
Curr Pediatr Rev; 2022; 18(3):226-236. PubMed ID: 34931965
[TBL] [Abstract][Full Text] [Related]
7. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)].
National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG
Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607
[TBL] [Abstract][Full Text] [Related]
8. Cancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients.
Gundavda MK; Gundavda KK
Curr Treat Options Oncol; 2021 Sep; 22(10):95. PubMed ID: 34515857
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
10. An overview on inactivated and live-attenuated SARS-CoV-2 vaccines.
Khoshnood S; Arshadi M; Akrami S; Koupaei M; Ghahramanpour H; Shariati A; Sadeghifard N; Heidary M
J Clin Lab Anal; 2022 May; 36(5):e24418. PubMed ID: 35421266
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
[TBL] [Abstract][Full Text] [Related]
12. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic.
Shao Y; Wu Y; Feng Y; Xu W; Xiong F; Zhang X
Front Med; 2022 Apr; 16(2):185-195. PubMed ID: 35226300
[TBL] [Abstract][Full Text] [Related]
14. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
[TBL] [Abstract][Full Text] [Related]
15. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 vaccines: concerns beyond protective efficacy and safety.
Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
[TBL] [Abstract][Full Text] [Related]
17. Myocarditis Following COVID-19 Vaccine Use: Can It Play a Role for Conditioning Immunization Schedules?
Esposito S; Caminiti C; Giordano R; Argentiero A; Ramundo G; Principi N
Front Immunol; 2022; 13():915580. PubMed ID: 35833128
[TBL] [Abstract][Full Text] [Related]
18. Are We Paving the Way to Dig Out of the "Pandemic Hole"? A Narrative Review on SARS-CoV-2 Vaccination: From Animal Models to Human Immunization.
Tardiolo G; Brianti P; Sapienza D; dell'Utri P; Dio VD; Rao G; Calabrò RS
Med Sci (Basel); 2021 Jul; 9(3):. PubMed ID: 34449681
[TBL] [Abstract][Full Text] [Related]
19. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
20. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
